PHP60 PRICING AND REIMBURSEMENT (P&R) IN BRIC COUNTRIES

Pharmaceutical Pricing and Reimbursement: Canada

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries

Objectives: The aim of this study was to review the requirements for the reimbursement of biosimilars and to compare the reimbursement status, market share, and reimbursement costs of biosimilars in selected Central and Eastern European (CEE) countries. Methods: A questionnaire-based survey was conducted between November 2016 and January 2017 among experts from the following CEE countries: Bulg...

Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries

Recently, the need for health care services has increased gradually and the limitations in sources allocated for this area have been recognized. Moving from this fact, it has gained a supreme importance to determine what health programs or technologies will be given priority. According to Danzon (Reference pricing: theory and evidence, reference pricing and pharmaceutical policy: perspectives o...

Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis.

The main objective of this comparative analysis was to assess regulations applied by EU governments to reward potentially innovative drugs. We focused on the pharmaceutical policy for in-patent drugs in seven EU countries: Belgium, France, Germany, Italy, the Netherlands, Spain, and the UK. A common scheme was applied to all seven countries: first, pricing and reimbursement procedures for new a...

Physician pricing and health insurance reimbursement

This study was based on physician claims records from three Blue Shield Plans. The principal results are: • Physicians are income-motivated. This means that income incentives can be incorporated into reimbursement systems to achieve specific ends, and that care should be taken to assure that new mechanisms do not create income incentives for physicians to act contrary to policy objectives. • Ph...